A randomized, crossover, phase I clinical study to evaluate bioequivalence and safety of tofacitinib and Xeljanz® in Chinese healthy subjects.
暂无分享,去创建一个
Yicheng Zhao | Xin-Ning Qu | Jing Lan | Renjie Zhang | W. Liang | Q. Ren | Guang-ping Liu | Yanli Wang | Zhengzhi Liu | Zhengjie Su | Qiaohuan Deng | Haimiao Yang | Zhongnan Xu | Jiahui Chen | Wanhua Wang | Yang Cheng | Shuang Yu | Yannan Zhou | Jing-Mei Yu | Wenzhong Liang